Sürdürülebilir Kalkınma Amaçları

• 4

Yazarlar

• Ural, Dilek(3)
• Emre, Ender(2)
• Ertas, Gokhan(2)
• Kozdag, Guliz(2)
• Akay, Yasar(1)
• Aygün, Fatih(1)
• Ertaş, Gökhan(1)
• Hebert, Kathy(1)
• Kiliç, Teoman(1)
• Kirbas, Ahu(1)
• Kozdaǧ, Güliz(1)
• Kutlu, Rasim(1)
• Memetoglu, Mehmet Erdem(1)
• Muratalievic, Tolkun Murataliev(1)
• Soran, Ozlem(1)
• Yaymaci, Mehmet(1)
• Çelikyurt, Umut(1)
• Şahin, Tayfun(1)

• MakaleAçık Erişim2013Scopus SJRQ3/r/gumushane/16018
  Comparison of the safety and efficacy of ivabradine and nebivolol mono- and combination therapies in the treatment of stable angina pectoris patients with left ventricular dysfunction

  Kutlu, Rasim; Memetoglu, Mehmet Erdem; Muratalievic, Tolkun Murataliev

  We aimed to investigate the pharmacoeconomic efficacy of ivabradine and nebivolol in treatment of stable angina pectoris patients with left ventricular dysfunction prospectively. Pharmacoeconomic analysis was performed by using cost minimization analysis, and cost effectiveness analysis. After 6 months' treatment LVEF for the nebivolol group (17 patients, 50%) improved by (38 +/- 6.5) to (41 +/- 3.2), (p>0.05) and for the ivabradine group (17 patients, 50%) (37 +/- 5.4) to (41 +/- 2.3), (p>0.05), mean MET value in the nebivolol group increased from (3.7 +/- 1.2) to (5.5 +/- 1.6), (p>0.05), versus from (3.6 +/- 1.5) to (5.5 +/- 1.4), (p>0.05) in the ivabradine group, cost minimization analysis results showed a difference in the total cost of treatment was US$ 5288.7 in favor of nebivolol. The findings suggest that nebivolol is more cost-effective than ivabradine in the treatment of patients with left ventricular dysfunction.

  • 
  AtıfWoS2·OpenAlex2

  İncele
• MakaleAçık Erişim2012Scopus SJRQ3/r/gumushane/16394
  Clinical effects of enhanced external counterpulsation treatment in patients with ischemic heart failure

  Kozdag, Guliz; Ertas, Gokhan; Aygün, Fatih; Emre, Ender; Kirbas, Ahu; Ural, Dilek; Soran, Ozlem

  Objective: Enhanced external counterpulsation (EECP) is a noninvasive treatment that is proven safe and effective in patients with coronary artery disease (CAD) and heart failure (HF). The aims of this study are to investigate the clinical effects of EECP therapy in patients with symptomatic CAD and chronic HF, and to find out an answer to the question: Does EECP therapy have any effect on the prognostic markers of HF? Methods: This study was designed as a prospective cohort study. A total of 68 consecutive patients with symptomatic CAD and chronic HF referred to EECP therapy were enrolled in this study between November 2007 and December 2010; 47 patients (39 males and 8 females, 65 +/- 7, years), have undergone EECP treatment, and 21 patients (20 males and 1 female, 62 +/- 10 years), who did not want to participate in the EECP program comprised the control group. Statistical analysis was performed using t tests for dependent and independent samples, Mann-Whitney U test, Chi-square and Fischer exact tests. Results: EECP therapy resulted in significant improvement in post-intervention New York Heart Association functional class (p<0.001), left ventricular ejection fraction (p<0.001), B-type natriuretic peptide levels (p<0.003), uric acid levels (p<0.05), free-T3/free-T4 ratio (p<0.034) and mitral annular E (p<0.05) velocity, compared with baseline, a finding not evident in the control group. Conclusion: EECP treatment significantly improved clinical and some biochemical parameters, which are mostly prognostic markers in patients with symptomatic CAD and chronic HE (Anadolu Kardiyol Derg 2012; 12:214-21)

  • 
  AtıfWoS7·OpenAlex17

  İncele
• MakaleYalnız künye2012Scopus SJRQ2/r/gumushane/16359
  Effect of enhanced external counterpulsation treatment on mean platelet volume in patients affected by ischemic chronic heart failure

  Ertas, Gokhan; Kozdag, Guliz; Emre, Ender; Akay, Yasar; Ural, Dilek; Hebert, Kathy

  Mean platelet volume (MPV) is increased in chronic heart failure (CHF) and is an independent predictor of mortality in CHF patients. It is not known whether enhanced external counterpulsation (EECP) therapy leads to decreased MPV values or not. The purpose of this study was to examine the effects of EECP on platelet count and MPV values and to assess the influence of MPV on the risk of death and recurrent ischemic events in ischemic CHF patients. A total of 68 ischemic heart failure patients with CHF symptoms and refractory angina pectoris were included in the study, 47 consecutive patients (39 males and eight females) aged 44-82 years. Although follow-up period started after completion of EECP in treated patients, control group follow-up started at the end of 7-week treatment without EECP. All patients were monitored for a mean duration of 13 +/- 8 months (range, 1-36 months). The primary endpoints of the study were effects of EECP treatment on platelets after treatment period (7 weeks) and the recurrence of ischemic events. Secondary endpoint was cardiovascular death during the follow-up period. We observed a significant increase in platelet count and decrease in MPV levels (P=0.044 and P=0.004, respectively) in the control group. There were no significant differences in platelet count and MPV levels in the EECP group (P>0.05). After the treatment period, New York Heart Association functional classification (2.60 +/- 0.75 vs. 1.72 +/- 0.68, P<0.001) and Canadian Cardiovascular Society functional classification of angina (2.50 +/- 0.90 vs. 1.60 +/- 0.74, P<0.001) improved in patients with EECP treatment. In our study, we found that EECP therapy had a neutral effect on MPV values and platelet count Blood Coagul Fibrinolysis 23:127-131 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

  • 
  AtıfWoS4·OpenAlex4

  İncele
• MakaleYalnız künye2012Scopus SJRQ2/r/gumushane/15681
  Aspirin, clopidogrel, and warfarin use and outcomes in a cohort of 580 patients discharged after hospitalization for decompensated heart failure

  Kozdaǧ, Güliz; Yaymaci, Mehmet; Ertaş, Gökhan; Çelikyurt, Umut; Şahin, Tayfun; Kiliç, Teoman; Ural, Dilek

  The benefits of taking of aspirin, clopidogrel, and warfarin in relation to cardiovascular mortality and re-hospitalization in chronic heart failure (HF) patients have been called into question. We examined the outcomes (cardiac mortality and/or HF re-hospitalization) in patients discharged from our hospital between January 2003 and July 2009 after hospitalization for chronic decompensated HF. Of 580 HF patients (mean age, 63 ± 13 years; mean ejection fraction, 26 ± 9%, 63% with coronary disease and 37% without coronary disease), 207 patients (36%) died due to cardiovascular reasons, and 313 (54%) required HF re-hospitalization for decompensated HF during a 39 ± 14 month follow-up period. 101 (17%) patients were taking clopidogrel during enrollment in the study. When comparing patients who were on clopidogrel treatment with those who were not, clopidogrel was found to have a beneficial effect on cardiac mortality (27 vs. 38%, P = 0.04). In conclusion, in this observational prospective study, patients who used clopidogrel showed decreased cardiac mortality [HR, 0.566 (95% CI 0.332-0.964), P = 0.036] compared to patients who did not take clopidogrel. Clopidogrel had a beneficial effect on the survival of chronic HF patients in the long term.

  • 
  AtıfScopus10·OpenAlex10

  İncele